

HC SURGICAL SPECIALISTS LIMITED

Incorporated in the Republic of Singapore

Registration No. 201533429G

ACQUISITION OF THE REMAINING 49% OF THE ISSUED AND PAID-UP SHARE CAPITAL IN JASON LIM ENDOSCOPY AND SURGERY PTE. LTD.

- ALLOTMENT & ISSUANCE OF CONSIDERATION SHARES

Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as used in the Company's announcements dated 23 August 2021 and 9 September 2023 in relation to the Acquisition (the "Announcements").

Further to the Announcements, the Board of Directors of HC Surgical Specialists Limited is pleased to announce that 4,914,277 Consideration Shares in the Company have been issued to Dr. Jason Lim today at an issue price of S\$0.3687 for each Consideration Share.

The Consideration Shares will be credited as fully paid-up and rank *pari passu* in all respects with the existing shares of the Company (save for any dividends, rights, allotments or other distributions that may be declared or paid, the record date for which falls before the date of issue of the Consideration Shares).

The Consideration Shares are subject to moratorium periods as set out in the Announcement dated 23 August 2021.

Following the issuance and allotment of the Consideration Shares, the total number of issued shares (including treasury shares) of the Company has increased from 151,395,630 to 156,309,907. The Consideration Shares are expected to be listed on 26 September 2023.

By Order of the Board

Dr. Heah Sieu Min
Executive Director and Chief Executive Officer

22 September 2023

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (the "Company") was incorporated on 1 September 2015 in Singapore and listed on Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies and general surgery services with a focus on colorectal procedures across a network of 15 clinics located throughout Singapore.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.